Freedom Capital Markets Starts Nutex Health (NUTX) at Buy

Freedom Capital Markets analyst Gene Mannheimer initiates coverage on Nutex Health (NASDAQ: NUTX) with a Buy rating and a price target of $56.00.

The analyst comments "We are initiating coverage of Nutex Health with a BUY rating and $56 target, equivalent to 7x our FY25 EBITDA estimate of $42M. While not a household name, Nutex’s micro-hospitals are launching throughout the nation, delivering easy access and convenience, lower cost and a superior, ‘concierge’ level of patient satisfaction, a welcome change from the broken and impersonal traditional hospital model. Nutex was crushed last year due to reimbursement changes under the No Surprises Act (NSA) but is re-emerging. We believe shares are undervalued and would be buyers of this micro-cap play leveraging an innovative and patient-focused healthcare model."

For an analyst ratings summary and ratings history on Nutex Health click here. For more ratings news on Nutex Health click here.

Shares of Nutex Health closed at $30.33 yesterday.

You May Also Be Interested In

• Morgan Stanley Downgrades Nevro Corp (NVRO) to Underweight
• BTIG Starts BrightView Holdings (BV) at Buy
• JPMorgan Upgrades Gap, Inc. (GAP) to Overweight